Neurogene Inc (NGNE) earnings · next report Nov 12, 2026
Next report
Thu, Nov 12, 2026
Before the open · In 8 days
Quarter ended Sep 2026
- EPS consensus
- −$1.49 Range −$1.59 – −$1.365 analystsYear ago −$0.99
- Revenue consensus
- $0 Range $0 – $08 analysts
EPS estimate trend
- 90 days ago−$1.28
- 60 days ago−$1.42
- 30 days ago−$1.42
- 7 days ago−$1.45
- Now−$1.45
Consensus −14.0% over 90 days. Last 30 days: 3 up, 3 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow NGNE into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 12)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- ±4.3% Absolute close-to-close move, 2 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$1.53
vs −$1.40 est. −9.3%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Missed EPS 2 quarters in a row
- Beat EPS in 2 of 4
- Aug 11, 2026MissEPS −$1.53GAAP vs −$1.40 −9.3%Rev — vs —
- May 13, 2026MissEPS −$1.39GAAP vs −$1.27 −9.1%Rev — vs —
- Mar 24, 2026BeatEPS −$1.13GAAP vs −$1.24 +8.9%Rev — vs —
- Nov 13, 2025BeatEPS −$0.99GAAP vs −$1.09 +9.2%Rev $0 vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Jun 2026 | −$1.40 | −$1.53GAAP | −9.3% | — | — | — |
| May 13, 2026 | Mar 2026 | −$1.27 | −$1.39GAAP | −9.1% | — | — | — |
| Mar 24, 2026 | Dec 2025 | −$1.24 | −$1.13GAAP | +8.9% | — | — | — |
| Nov 13, 2025 | Sep 2025 | −$1.09 | −$0.99GAAP | +9.2% | — | $0SEC | — |
Earnings documents
- Earnings press releaseEX-99.1 · 8-K filed Aug 11, 2026Open on SEC.gov
- Supplemental materialsEX-99.2 · 8-K filed Aug 11, 2026Open on SEC.gov
Read the filing on LicianEDGAR filing index
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
NGNE is rated 1.66 of 5 among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- RGNX earnings1.69 · Sell · stock
- MDGL earnings1.68 · Sell · stock
- MNPR earnings1.67 · Sell · stock
- WVE earnings1.67 · Sell · stock
- CABA earnings1.65 · Sell · stock
- GLSI earnings1.64 · Sell · stock
- KRRO earnings1.64 · Sell · stock
- OCUL earnings1.63 · Sell · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$1.53 | — |
| Q1 FY26 | — | −$1.39 | — |
| Q3 FY25 | — | −$0.99 | — |
| Quarter (Sep 2025) | — | −$0.99 | — |
Neurogene Inc (NGNE) is a biotechnology company listed on US.
Latest reported NGNE revenue for 2025-12-31 was $0. Net income was -$90.4M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. NGNE currently screens at market cap $286.5M.
When the next NGNE 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was down 100.0% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full NGNE research stays on the stock page; the tape stays on the quote page.
NGNE earnings FAQ
When is NGNE's next earnings date?
Neurogene Inc (NGNE) is expected to report on Thu, Nov 12, 2026, before the open. The provider lists the session, which it sets once the company announces. Consensus EPS is −$1.49.
Did NGNE beat earnings estimates last quarter?
No. On Aug 11, 2026 Neurogene Inc (NGNE) reported adjusted EPS of −$1.53 against a −$1.40 consensus (−9.3%), a miss.
How often does NGNE beat EPS estimates?
Neurogene Inc (NGNE) beat the EPS consensus in 6 of its last 10 reported quarters.
What is NGNE's latest net income?
Latest cached Neurogene Inc (NGNE) net income was -$90.4M. Statements: https://lician.com/financials/ngne
What is NGNE's latest diluted EPS?
Latest cached Neurogene Inc (NGNE) diluted EPS for Dec 31, 2025 was -$4.24.
What period does the latest NGNE earnings print cover?
The latest cached Neurogene Inc (NGNE) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
Where are NGNE earnings listed?
Cached earnings facts for Neurogene Inc (NGNE) are listed at https://lician.com/earnings/ngne. Statements: https://lician.com/financials/ngne
Not investment advice.